-
张力
上榜理由：
自1986年以来，他一直在中山医科大学肿瘤防治中心从事肿瘤化疗医疗、教学和科研工作及抗癌药物的临床研究，主持（PI）国际多中心临床研究一项、国家级多中心临床研究三项，参与20多项国际多中心临床研究。在国内核心期刊发表论文60余篇。张力医生为人热情，对工作细心负责，对病人真诚相待，是患者心中的好医生。所属医院：中山大学附属肿瘤医院
所属科室：内科
医生职称：教授 主任医师
擅长疾病：肺癌、鼻咽癌和大肠癌等常见肿瘤的内科治疗和多学科综合治疗，同时对晚期癌症病人的对症支持治疗如：癌性贫血的治疗、恶性肿瘤骨转移的治疗、化疗导致的恶心呕吐治疗、晚期病人的疼痛的治疗。
介绍：
1963年3月出生，河南洛阳人。中共党员。教授、主任医师、肿瘤内科博士生导师。1986年毕业于中山医科大学临床医学系，获得学士学位。1991年中山医科大学临床肿瘤学硕士毕业，获得硕士学位。先后赴法国巴黎Institut Gustave Roussy肿瘤中心、美国Fox Chase肿瘤中心、美国M.D.Anderson肿瘤中心进修。现任中山大学附属肿瘤医院内科副主任，中山大学肺癌研究中心副主任，中山大学附属肿瘤医院国家新药(抗肿瘤药物)临床研究(GCP)中心主任、I期病房主任，国家药品食品监督管理局(SFDA)药物评审咨询专家、澳门镜湖医院放射治疗中心顾问医生。并先后任中国抗癌协会肿瘤康复与姑息治疗专业委员会副主任委员、化疗专业委员、肺癌专业委员会委员;广东省抗癌协会肿瘤康复与姑息治疗专业委员会主任委员，广东省抗癌协会化疗专业委员会、肺癌专业委员会副主任委员等职位。主要研究方向：肺癌和鼻咽癌等实体瘤的化学治疗、靶向治疗、多学科综合治疗以及晚期癌症的姑息治疗。发表SCI论文40余篇，国内核心期刊论文70余篇。主编及参与编写肿瘤专业的专著9本。荣获广东省科学技术研究成果三等奖(第一完成人)和广东医药卫生科技进步奖三等奖(第四完成人)。
海外留学经历：
1996年赴法国巴黎Institut Gustave Roussy(IGR)肿瘤中心短期进修。
1998年赴美国费城Fox Chase肿瘤中心短期进修。
2001-2002年在美国德州大学M.D.Anderson肿瘤中心进修。
临床医疗经验：
自1986年一直在中山医科大学肿瘤防治中心从事肿瘤化疗医疗、教学和科研工作及抗癌药物的临床研究，擅长肺癌、鼻咽癌和大肠癌等实体瘤的化学治疗、靶向治疗、多学科综合治疗。同时对晚期癌症病人的对症支持治疗如：癌性贫血的治疗、恶性肿瘤骨转移的治疗、化疗导致的恶心呕吐治疗、晚期病人的疼痛的治疗等方面也有较深入的研究。负责执笔撰写中国版《NCCN非小细胞肺癌临床指导原则》、《双磷酸盐治疗肺癌骨转移的专家共识》及《肿瘤相关贫血治疗专家共识》等多个临床共识，参与撰写《NCCN结肠/直肠癌临床指导原则》、《NCCN头颈癌临床指导原则》、《表皮生长因子受体抑制剂导致皮疹治疗的专家共识》。在国内最早开展和应用放疗前的诱导化疗治疗局部晚期鼻咽癌和大剂量醛氢叶酸+5FU持续滴注48小时(双周疗法)治疗晚期大肠癌的临床研究、非铂类方案治疗晚期非小细胞肺癌、分子靶向用于非小细胞肺癌的维持治疗的临床研究。在国内首创癌痛规范化治疗示范病房(GPM)项目，并将该项目成功向全国推广。目前担任卫生部合理用药专家委员会抗肿瘤药专业组成员、卫生部癌痛规范化治疗专家组副组长、广东省干部保健专家、广州市干部保健专家。
科学研究经验：
对抗癌新药临床研究的程序、原则、组织和实施有非常丰富的实际操作经验，主持或作为主要参与者的药物临床研究包括：卡铂、长春瑞滨、多西紫杉醇、草酸铂、马蔺子素胶囊、rhG-CSF、帕米磷酸二钠、拓扑替康、吉非替尼、厄洛替尼、埃克替尼、阿帕替尼、法米替尼、昔妥西单抗、贝伐单抗、培美曲赛、S-1、血管内皮抑素等。直接参与一些国家创新(I类新药)药物(如：有机锗、肿瘤坏死因子、基因工程溶瘤腺病毒H101、基因工程腺病毒-TK基因治疗、埃克替尼、阿帕替尼、法米替尼、长效血管内皮抑素、氟拉哌索、Aflibercept)的药代动力学研究和临床试验观察工作。主持(PI)国际多中心临床研究一项、国家级多中心临床研究十多项，参与30多项国际多中心临床研究、担任多个国际多中心研究的独立数据管理委员会(IDMC)成员和专家委员会(SC)成员。受国家药品食品监督管理局(SFDA)委托负责起草《抗肿瘤药物临床研究技术指导原则》(2006年，第二版)。近年来分别承担和参与了多项国家级科技攻关的科研基金(包括九五、十一五、1035计划项目、863项目、973项目、新药创制国家重大专项)、广东省自然科学基金、广东省重点科技攻关基金、广东省医学科研基金、广州市科技局基金等研究。参与中山大学附属肿瘤医院国家级抗癌药物临床试验研究中心的论证、筹建工作。成功组织和筹备每年度的广东省抗癌协会化疗专业委员会会议，以及国家级继续教育项目GCP培训班等。在SCI杂志发表论文40篇，其中包括第一作者或通讯作者的文章如：《Lancet Oncology》(SCI=22.589，第一及通讯作者)、《Journal of Clinical Oncology》(SCI=11.81，第一及通讯作者)、《Annals Oncology》(SCI=6.425，通讯作者)《European Journal of Cancer》(SCI=4.47通讯作者)、《Journal of Thoracic Cancer》(SCI=4.5通讯作者)、《Lung Cancer》(SCI=3.46，第一作者)、《Cancer Gene Therapy》(SCI=3.89，通讯作者)、《Cancer Chemotherapy and Pharmacology》(SCI=2.2，第一作者)等22篇，作为作者之一的文章如：《Journal of Clinical Oncology》(SCI=17.3)、《Lancet Oncology》(SCI=13.28)、《Cancer》(SCI=4.8)、《Journal of Thoracic Oncology》(SCI=3.5)、《Oncology》(SCI=1.9)、《Clinical Lung Cancer》等文章18篇。在国内核心期刊发表论文90余篇。主编及参与编写肿瘤专业的专著有9本。获广东省科学技术研究成果三等奖(第一完成人)、广东医药卫生科技进步奖三等奖(第四完成人)各一次。
教学工作经验：
自1986年至今一直在中山医科大学肿瘤防治中心内科从事肿瘤化疗本科生和进修医生的临床教学工作，担任本科生临床见习带教两次、1995年兼任本科生兼职班主任一次(一年)、一年制进修医生班主任一次。从1997年担任内科副主任后一直分管教学工作至2008年。1998年开始招收临床型硕士研究生，现共培养临床型硕士生12名、科研型硕士2名、七年制硕士3名、留学生1名。2009年开始招收博士研究生5名。获中山医科大学青年教师讲课比赛三等奖一次。
科研获奖项目：
1.《5-氟尿嘧啶/醛氢叶酸双周疗法治疗恶性肿瘤》 广东省科学技术研究成果三等奖，2006年度，排名第一
2.《晚期鼻咽癌化学治疗的研究》 广东省医药卫生科技进步奖三等奖，1998年度，排名第四
科研基金：
2002年以前获得获得科研基金：
1.广东省医学科研基金：重组腺病毒的药代动力学及毒理学研究(A2001042)(2001-2003年)李苏、张力、王安训、廖海、何友兼
2.广东省医学科研基金：5-FU靶酶及其代谢酶生物多态性与结直肠癌化疗疗效之相关性的研究(A2001222)(2001-2003年)张力、潘志忠、陈功、钱晓洲、夏忠军、李苏、廖海
3.国家高技术研究发展计划(“863”计划)：H101基因工程腺病毒的中试研究(分题)(102-1202-06)(2000-2002年)张力、徐瑞华、夏忠军、廖海、李苏
4.国家医药技术创新项目：筛选逆转肿瘤细胞对顺氯氨铂(DDP)的抗药性逆转剂(96-901-06-73)(2000-2001年)徐瑞华、符立梧、廖海、姜文奇、李苏、梁永钜、管忠震、张力
5.广州市科技计划项目：粉防己碱临床逆转乳癌、骨肉瘤多药抗药性的研究(2000-Z-110-08)(2000-2003年)杨小平、姜文奇、沈靖南、符立梧、梁永钜、张力、李苏、王晋、苏秀容、汤昊
6.广东省百项工程项目：新药临床试验研究中心(GCP)(99B07902Q)(1999-2002年)姜文奇、张力、徐瑞华、刘冬耕、黄民、徐光川、黄慧强、谭悦、廖海、周中梅
7.广东省重点科技攻关项目：粉防已碱临床逆转肿瘤多药抗药性研究(99M04401G)(1999-2002年)符立梧、姜文奇、杨安奎、周晏、徐瑞华、张力、梁永钜、潘启超
8.广东省重点科技攻关项目：恶性淋巴瘤临床特征与细胞周期调节蛋白及基因变异关系的研究(99M04911G)(1999-2002年)徐瑞华、姜文奇、邵建永、张力、孙晓非、周中梅、侯景辉、管忠震
9.广东省医药科研基金：弥漫性大B细胞淋巴瘤预后与细胞周期调控蛋白的关系(A1999208)(1999-2001年)徐瑞华、姜文奇、邵建永、周中梅、张力、喻庆薇、侯景辉
2002年
1.国家高技术研究发展计划(863计划)：临床试验关键技术及平台研究(2002AA2Z34IC)姜文奇、管忠震、张力、徐瑞华、夏忠军、苏苏、黄民、刘冬耕、孙晓非、黄慧强、李志铭、李建红、曹烨、郭颖
2.广东省医学科研基金：I-III期非小细胞肺癌现代治疗的新策略和多学科协作模式的建立(A2002229)王欣、张力、戎铁华、卢泰祥、陈明、吴秋良、马刚、林鹏、杨学宁、黄培钰
2004年
1.广东省科技计划项目：组织微阵列方法分析NSCLC含铂方案化疗敏感性相关性研究(2004B30301006)张力、张阳、徐菲、李宁、李苏、张星、廖海、汪波、侯景辉、郭颖
2.广东省科技计划项目：N2期非小细胞肺癌新辅助治疗策略的临床研究(2004B30301008)王欣、戎铁华、张力、陈明、郑列、张惠忠、马刚、王旭东、王春梅、王军业
2005年
1.“985工程”二期建设项目：酪氨酸激酶抑制剂在鼻咽癌中应用的临床与实验研究。张力、黄培钰、李苏、张星、廖海、汪波、侯景辉
2006年
1.广东省科技计划项目：以分子标记物预测和预防非小细胞肺癌骨转移的基础和临床研究 (2006B36002004)张力、王欣、汪波、云径平、侯景辉、侯雪、林丽珊
2.“十一五”国家科技支撑计划：常见恶性肿瘤预防、早诊及综合治疗研究项目非小细胞肺癌规范化多学科综合治疗的多中心协作研究(课题2)(主要参加人员)
2007年
1.广东省自然科学基金：EGFR-TKI治疗肺癌的基因组学及蛋白质组学研究(07001532)张力、王欣、李苏、廖海、黄河、张阳、赵洪云、田莹、林立平、吴烜
2.国家高技术研究发展计划(863计划)课题：鼻咽癌的分子分型和个体化诊疗(2006AA02A404)(molecular classification, personalized diagnosis and therapy of nasopharyngeal carcinoma.)子课题：鼻咽癌个体化化疗和分子靶向治疗的探索。张力、李宇红、麦海强、曹素梅、黄培玉、洪明晃、郭翔
2008年
1. 新药创制国家重大专项：临床试验评价技术平台(2008ZX09312-002)(Major science and technology project of "National Significant new drug creation")。子课题：新型靶向药物临床研究的探索
2. 新药创制国家重大专项：埃克替尼子课题(2008ZX09101-11)：埃克替尼治疗晚期非小细胞肺癌的II/III期临床研究。张力、史艳侠、陈丽昆、黄岩
2009年
1.吴阶平医学基金会(08-JC-003)：比较500mg吉非替尼与250mg吉非替尼用于经吉非替尼治疗1月后疾病稳定的晚期非小细胞肺癌患者的随机II期临床研究(2009-2011)张力、邓燕明、张为民、贾筠、董维(250万)
2010年
1. CSCO血管靶向治疗基金：肿瘤内微血管密度(MVD)预测贝伐单抗(Bev)联合化疗的疗效的研究。(2010-2012)张力、陈丽昆、黄岩、梁颖(20万)
2. 广州市科技计划项目：FCγR基因多态性预测爱必妥治疗NSCLC疗效价值的临床研究。(2010-2012)张力、史艳侠、陈丽昆、黄岩、田莹、赵媛媛、蒋玮、薛聪(15万)
2011年
1. 广东省卫生厅基金(A2011203)：miR7与EGFR-TKI用药疗效相关性的实验研究。(2010-2012)黄岩、赵洪云、田莹、赵媛媛、薛聪、王树森、张力(2万)
2. 勃林格殷格翰：BIBF1120治疗鼻咽癌的临床前研究
3. 勃林格殷格翰：BIBW2992治疗鼻咽癌的临床前研究
4. 吴阶平医学基金会(320672010015)：Notch信号对非小细胞肺癌EGFR通路的调节作用及联合靶向治疗的机制研究。(2010-2011)谢勉，张力(7万)
5. 吴阶平医学基金会(320674010012)：测定晚期NSCLC患者EGFR-TKI治疗前后外周血EGFR下游通路蛋白表达变化与预测EGFR-TKI治疗疗效价值的研究。(2010-2012)黄岩、赵洪云、赵媛媛、薛聪、张力(7万)
6. *制药有限公司：c-met抑制剂在鼻咽癌中的体内体外研究
2012年
1. 国家自然科学基金青年科学基金项目(81201718)：氟尿嘧啶相关酶调控作用下5FU剂量个体化治疗模型的建立。(2013-2015)赵洪云、买世娟、赵媛媛、张剑威、黄岩、王志强、赵利平、田莹、张力(23万)
2. 广东省科技计划项目(2012B031800280): 转录共活化因子p300在非小细胞肺癌侵袭性发展中的作用。(2013-2015)侯雪、杨浩贤、张力、孙健、吴烜、薛聪、赵媛媛、徐理华、罗容珍、侯景辉(5万)
3. 吴阶平医学基金会(?)：肿瘤相关炎症因子对表皮生长因子受体-酪氨酸激酶抑制剂治疗非小细胞肺癌耐药的影响及机制探讨。(2012-2014)吴烜，张力(5万)
4. 广东省自然科学基金(S2012040007455)：氟尿嘧啶相关酶调控作用下鼻咽癌5FU剂量个体化治疗模型的建立。(2012-2014)赵洪云、张剑威、赵媛媛、黄岩、王志强、赵利平、田莹、张力(3万)
5. “863”高技术研究发展计划资助重大项目：“重大疾病的分子分型与个体化诊疗技术”之“肺癌的分子分型和个体化诊疗技术”(2012AA02A502)(National High Technology Research and Development Program of China 2012AA02A502)子课题。张力、吴煊、胡志皇、方文峰、黄岩、赵洪云(30万)
6. “863”高技术研究发展计划资助重大项目：“重大疾病基因组技术”和“分子分型与个体化诊疗技术”之“鼻咽癌的分子分型和个体化诊疗技术”(2012AA02A501)(National High Technology Research and Development Program of China 2012AA02A501)子课题。张力、黄岩、吴煊、胡志皇、方文峰、赵洪云(50万)
7. 国家科技重大专项项目：重大新药创制之“基于高通量实时细胞筛选平台和大容量化合物库的新药研发基地”(Innovative drug R&D center based on real-time high-throughput cell-based screening platformand large capacity compound library)之“分子靶点抗肿瘤新药临床研究”(2013ZX09401003-002)子课题。张力、李苏、陈丽昆、赵洪云、赵媛媛、方文峰、毕炳添(200万)
2013年
1. 吴阶平基金课题(320.6750.1316)：外周血肿瘤细胞计数及耐药相关分子改变动态监测在EGFR突变阳性晚期非小细胞肺癌患者接受EGFR-TKI治疗疗效预测、评估及耐药机制研究中的作用。张力、黄岩、方文峰、赵媛媛、吴煊、梁文华、田莹、杨云鹏(200万)
主编或编写专著：
1.《实用头颈肿瘤学》华南理工大出版社，1999年第一版，参加编写，
2.《临床肿瘤学》(高校教材)科学出版社，1999年第一版，2005年第二版，参加编写，ISBN 7-03-015941-1
3.《社区肿瘤学》科学出版社，2000年第一版，参加编写，2008年第二版，参加编写 ISBN 978-7-03-022470-5
4.《肿瘤化疗处方手册》广东科技出出版社，2003第一版，2005年第二版，主编
5.《肿瘤生物治疗学》广东科技出版社，2005第一版，参加编写
6.《食道胃肠道癌》(中国抗癌协会科普系列丛书)人民卫生出版社，2005第一版，参加编写
7.《临床肿瘤学》(国家级继续医学教育项目教材)中国医学电子音像出版社，2006第一版，参加编写
8.《肿瘤学专题讲座》(名院学术厅丛书)郑州大学出版社，2006第一版，参加编写 ISBN 7-81106-266-6
9.《乳腺癌肺癌骨转移诊疗规范建议-专家共识解读》(中华医学继续教育视听杂志)中国医学电子音像出版社，ISBN 7-900191-80-1/R?80，2006;主讲
10.《非小细胞肺癌规范诊疗进展》(中华医学继续教育视听杂志)中国医学电子音像出版社，ISBN 978-7-900220-71-4/R?71，2007;主讲
11.《恶性肿瘤骨转移及骨相关疾病临床诊疗专家共识》(2007年版)中国协和医科大学出版社，ISRC CN-A37-07-0006-0/V.R(光碟版)，2007;主讲
12.《恶性肿瘤骨转移及骨相关疾病临床诊疗专家共识》(2008年版)中国协和医科大学出版社，ISRC CN-A37-08-0002-0/V.R(光碟版)，2008;主讲
13.《恶性肿瘤骨转移及骨相关疾病临床诊疗专家共识》北京大学医学出版社，2008年8月，第一版，ISBN 978-7-81116-125-0，参加编写。
14.《肿瘤分子靶向治疗》人民卫生出版社，2009年5月，第一版，ISBN 978-7-711-11332-8，编委。
15.《临床肿瘤学高级教程》(高级卫生专业技术资格考试指导用书) 人民军医出版社，2011年11月，第一版，ISBN 978-7-5091-5170-9，编委。
16.《肺癌》张兰军、张力主译
17.《个体化医学原则》人民卫生出版社，2013年1月，第一版，ISBN 978-7-117-16476-4/R?16477，副主编。
2002-2011年发表论文:
第一作者或通讯作者：
1. 鼻咽癌患者血浆EB病毒DNA水平的动态变化与临床疗效的关系.《癌症》2002, 21(8):817-822
2. HPLC法测定血浆中卡铂的AUC.《中国临床药理学杂志》2002, 18(4)：294-296
3. 开普拓治疗大肠癌的临床应用.《中华肿瘤杂志》2003,25(6):607-609
4. 吉西他滨加依托泊苷方案治疗晚期非小细胞肺癌的II期临床研究.《中国癌症杂志》 2004, 14(1):59-60
5. 鼻咽癌患者血浆EB病毒DNA水平的动态变化与肿瘤复发关系.《临床肿瘤学杂志》2004, 9(2):122-125
6. 晚期非小细胞肺癌组织中ERCC-1、Metallothionein、p53表达与铂类耐药性及预后的相关性分析.《癌症》 2004, 23(7):845-850
7. 吉西他滨联合顺铂与吉西他滨联合诺维本治疗晚期非小细胞肺癌的临床研究.《癌症》2004, 23(11s):1455-1458
8. 中国非小细胞肺癌患者表皮生长因子受体突变的研究.《癌症》2005, 24(8):919-923
9. Li Zhang, Chong Zhao, Pei-Jian Peng, Li-Xia Lu, Pei-Yu Huang, Fei Han, and Shao-Xiong Wu: Preliminary Results of Randomized Phase III ClinicalStudy Comparing Standard Radiotherapy With orWithout Weekly Oxaliplatin in Treatment ofLocoregionally Advanced Nasopharyngeal Carcinoma. Journal of Clinical Oncology 2005; Vol 23(33): 8461-8468(SCI=11.81)
10. 晚期非小细胞肺癌治疗新进展.《中国肺癌杂志》 2005, 8(5):375-377
11. 吉西他滨联合顺铂与吉西他滨联合去甲长春碱方案治疗非小细胞肺癌疗效的比较.《中国肺癌杂志》 2005, 8(6):580-584
12. 组织微阵列方法分析晚期非小细胞肺癌患者HER2蛋白表达及其临床意义.《中国肺癌杂志》2006, 9(1):50-54
13. Erlotinib在肺癌应用中的相关分子和临床预后指标.《循证医学》2006, 6(1):10-13
14. 血浆EB病毒DNA浓度预测鼻咽癌远处转移的研究.《癌症》 2006, 25(7):785-792
15. 贝伐单抗与埃罗替尼联合治疗复发性非小细胞肺癌患者的I/II期临床经验.《循证医学》2006, 6(4):213-215
16. 国产多西紫杉醇治疗晚期非小细胞肺癌的随机对照临床研究.《癌症》2006, 25(8):999-1002
17. 重组人红细胞生成素大剂量冲击维持疗法治疗30例肿瘤相关贫血的临床报告.《癌症》 2006, 25(9):1120-1122
18. Gefitinib记名供药计划(EAP)治疗晚期非小细胞肺癌患者的临床研究结果.《癌症》2006, 25(12):1561-1564
19. 原发性小肠腺癌 50例临床分析.《临床肿瘤学杂志》 2006, 11(5):358-360
20. 放射治疗同期合并每周奥沙利铂治疗局部晚期鼻咽癌的随机Ⅱ期临床对照研究.《中国肿瘤临床》 2006, 33(17):995-998
21. 非小细胞肺癌辅助化疗的热点问题.《中华结核和呼吸杂志》2007, 30(2):86-87
22. Bijesh Raj Ghimire，林立平，郭颖，张力:同期化放疗与单纯放疗在局部晚期鼻咽癌中的作用：一项关于III期随机试验的荟萃分析.《循证医学》2007, 6(4):213-215
23. 吉非替尼治疗化疗失败的局部晚期或转移性非小细胞肺癌疗效及生存的预测因素.《中国肺癌杂志》 2007, 10(5):411-417
24. Li Zhang, Yang Zhang, Pei-Yu Huang, Fei Xu, Pei-Jian Peng, Zhong-Zhen Guan: Phase II Clinical Study of Gemcitabine in the treatment of patients withadvanced nasopharyngeal carcinoma (NPC) after the failure of platinumbased chemotherapy. Cancer Chemotherapy and Pharmacology2008; Vol 61(1):33-38(SCI=2.2)
25. 应用荧光原位杂交方法检测鼻咽癌细胞系中 EGFR基因拷贝数变化.《实用癌症杂志》2008, 23(4):390-392
26. 晚期非小细胞肺癌一线化疗疗效与生存关系的分析.《中国肺癌杂志》2008, 11(3):333-338
27. 晚期非小细胞肺癌的二线治疗进展.《中国肺癌杂志》 2008, 11(1):4-9
28. 厄罗替尼治疗晚期非小细胞肺癌患者的临床疗效.《癌症》 2008, 27(4):393-399
29. 非小细胞肺癌小肠转移1例报告和文献复习.《癌症》2008, 27(4):447-448
30. 化疗在不可切除III期(N2)非小细胞肺癌中的作用.《中国肺癌杂志》 2008, 11(5):657-662
31. Relationship between expression of CEA, E-cadherin and liver metastasis in colorectal cancer. Chinese Journal of Clinical Oncology 2008; Vol 5 (6):429-432
32. 组织芯片技术分析c-kit蛋白在鼻咽癌组织中的表达及其临床意义 .《临床肿瘤学杂志》2009, 14(2):97-101
33. C-KIT基因在鼻咽癌患者中的突变.《中国癌症杂志》2009, 19(4):266-269
34. 鼻咽、肺双原发癌一例病例报告和文献复习.《中国肺癌杂志》 2009, 12(1):86-89
35. 吉非替尼对鼻咽癌细胞抑制作用及其对 EGFR 表达影响的探讨.《中华肿瘤防治杂志》 2009, 16(13):978-981
36. Xu Fei, Li Su, Li Xiao-ling, Guo Ying, Zou Ben-Yan, Xu Ran, Liao Hai, Zhao Hong-Yun, Guan Zhong-Zhen, Zhang Li: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor. Cancer Gene Therapy 2009; Vol 16:723-730(SCI=3.89)
37. Li Zhang, Xue Hou, Shun Lu, Huilan Rao, Jinghui Hou, Rongzhen Luo,He Huang, HongyunZhao, Hong Jian, Zhiwei Chen, Meilin Liao, Xin Wang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study. Lung Cancer 2010; Vol 67:114-119(SCI=3.14)
38. 鼻咽癌细胞株中C-Kit表达和突变以及对Imatinib的反应性.《癌症》 2010; 29(2):137-142
39. Wei Jiang, Yang Zhang, Hongyun Zhao, Guangchuan Xu, Liping Lin, Yuanyuan Zhao, Cong Xue, Li Zhang:Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer.Chinese Journal of Lung Cancer2010;Vol 13(3):211-215
40. RRM1和 ERCC1对早期非小细胞肺癌术后生存的预测作用. 《循证医学》 2010, 10(1):17-22
41.非小细胞肺癌患者K-RAS基因突变的研究.《中国肺癌杂志》2010, 13(6):602-606
42. Wang, Fenghua; Jiang, Fanggong; Li, Yuhong; Guo, Ying; Shen, Lin; Zhang Li:The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in AdvancedGastric Cancer: A Systematic Review and Pooled Analysis of theChinese Literature. Current Cancer Therapy Reviews 2010;Vol 6 (3):214-221.
43. Liang-ping Xia; Hui-juan Qiu; Xu-xian Chen; Pi-li Hu; Gui-fang Guo; Fang Wang; Fei-fei Zhou; Wen-zhuo He; Bei Zhang; Li Zhang: Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Medical Oncology2010; Vol28(1):570-576 (SCI=1.227)
44. Li Zhang, Chong Zhao, Bijesh Ghimire, Ming-Huang Hong, Qing Liu, Yang Zhang, Ying Guo,Yi-Jun Huang, Zhong-Zhen Guan：The Role of Concurrent Chemoradiotherapy in the Treatment of Locolregionally Advanced Nasopharyngeal Carcinoma among Endemic Population: A Meta- analysis of the Phase III Randomized Trials. BMC Cancer 2010; Vol 10:558 (SCI=2.74)
45. Li Zhang, Su Li, Yang Zhang, Jing Zhan, Ben-Yan Zou, Robert Smith, Paul D Martin, Yinrui Jiang, Hai Liao, Zhong-zhen Guan: Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumours: An Open-Label, Phase I, Rising Multiple Dose Study. ClinicalTherapeutics, 2011; Vol 33(3): 315–327 (SCI=3.28)
46.Xue Hou, Chong Zhao, Ying Guo, Fei Han, Li-Xia Lu, Shao-Xiong Wu, Su Li, Pei-Yu Huang, He Huang, Li Zhang:Different Clinical Significance of Pre- and Post-treatment Plasma Epsteine Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy. Clinical Oncology 2011; Vol 23: 128-133 (SCI=2.85)
47.Yuan-Yuan Zhao, Cong Xue, Xue Hou, Hai Liao, Su Li, Hong-Yun Zhao, YanHuang, Li-Kun Chen, Fei Xu, Jun-Ling Liu, Li Zhang: Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. European Journal of Cancer 2011; Vol 47:848-853 (SCI=4.47)
48.Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen,Yan-Xia Shi, Li Zhang:Validation of a clinical prognostic modelinChinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.Medical Oncology 2011; Vol28(1):331-5(SCI=2.21)
49.Yuan-Yuan Zhao, Su Li, Yang Zhang, Hong-Yun Zhao, Hai Liao, Ying Guo, Yan-Xia Shi, Wei Jiang, Cong Xue, Li Zhang:The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Medical Oncology 2011; Vol 28(3):697-702(SCI=2.21)
50.Yuan-Yuan Zhao, Cong Xue, Wei Jiang, Hong-Yun Zhao, Yan Huang, Kristin Feenstra, James H. Resau, Chao-Nan Qian, Li Zhang:Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.Journal of Thoracic Oncology2012; Vol 7(1):71-75(SCI=3.66)
51. Li Zhang, Shenglin Ma, Xiangqun Song, Baohui Han, Ying Cheng, Cheng Huang, Shujun Yang, Xiaoqing Liu, Yunpeng Liu, Shun Lu, Jie Wang, Shucai Zhang, Caicun Zhou, Xiangwei Zhang, Nobuya Hayashi, Mengzhao Wang: Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) Lancet Oncology 2012;Vol 13:466-475 (SCI=22.589)
52.Pei-Yu Huang, Yan Li, Hai-Qiang Mai, Rong-Zhen Luo, Yu-Chen Cai, Li Zhang: Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncology 2012; Vol 48(10):964-968 (SCI=2.857)
53. Cong Xue, Zhihuang Hua, Wei Jiang, Yuanyuan Zhao, Fei Xu, Yan Huang, Hongyun Zhao, Jingxun Wu, Yang Zhang, Liping Zhao, Jing Zhang, Likun Chen, Li Zhang: National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012; Vol 77(2):371-375 (SCI=3.43)
54. Cong Xue, Xi Wang, Roujun Peng, Yanxia Shi, Tao Qin, Donggen Liu, Xiaoyu Teng, Shusen Wang, Li Zhang and Zhongyu Yuan: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Science 2012;Vol 103(9):1679-1687(SCI=3.325)
55. Yang Zhang, Liping Zhao, Peiyu Huang, Jingxun Wu, Fenghua Wang, Yan Huang, Li Zhang: Open-Label Single-Arm Phase II Study of Pemetrexed in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy. Cancer Chemotherapy and Pharmacology2012; Vol 70(4):611-615(SCI=2.2)
56.Jianwei Zhang, Yan Huang, Xiaoling Li, Ying Guo, Yuanyuan Zhao, Cong Xue, Zhihuang Hu, Li Zhang, Hongyun Zhao: The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLCfrom one institution. Onco Targets and Therapy 2012, Vol 5:349–355 (SCI=1.26)
57. Fei Xu, Jingxun Wu, Yuanyuan Zhao, Cong Xue, Wei Jiang, Liping Lin, Xuan Wu, Yachao Lu, Hua Bai, Jiasen Xu, Guanshan Zhu, Li Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutationsin peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets and Therapy 2012, Vol 5:439-447 (SCI=1.26)
58. Yan Huang, Jing Zhang, Yuan-Yuan Zhao, Wei Jiang, Cong Xue, Fei Xu,Hong-Yun Zhao, Yang Zhang, Li-Ping Zhao, Zhi-Huang Hu, Zhi-Wen Yao,Qian-Yong Liu and Li Zhang: SPARC expression and prognostic value in non-small cell lung cancer. Chinese Journal of Cancer 2012; Vol31(11):541-548
59. Zhao LP, Xue C, Zhang JW, Hu ZH, Zhao YY, Zhang J, Huang Y, Zhao HY, Zhang L. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer. 2012 Oct;31(10):476-8362.
60. Hongyun Zhao, Yan Huang, Cong Xue,Yang Chen, Xue Hou, Ying Guo,Liping Zhao, Zhi huang Hu, Yujie Huang, Yongzhang Luo, Li Zhang: Prognostic significance of cell surface nucleolin expression in postoperative non-small cell lung cancer. PLos One 2013; Vol 8(1):e54674 (SCI=4.09)
61.C. Xue, Y. Huang, P. Y. Huang, Q. T. Yu, J. J. Pan, L. Z. Liu, X. Q. Song, S. J. Lin, J. X. Wu, J. W. Zhang, H. Y. Zhao, F. Xu, J. L. Liu, Z. H. Hu, L. P. Zhao, Y. Y. Zhao, X Q . Wu, J. Zhang, Y. X. Ma,2&L. Zhang：Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Annals of Oncology 2013; Vol 24:1055-1061 (SCI=7.384)
62.X. Wu, P. Y. Huang, P. J. Peng, L. X. Lu, F. Han, S. X. Wu, X. Hou, H. Y. Zhao, Y. Huang, W. F. Fang, Y. Y. Zhao, C. Xue, Z. H. Hu, J. Zhang, J. W. Zhang, Y. X. Ma, W. H. Liang, C. Zhao, L. Zhang: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology 2013 Aug;24(8):2131-6; (SCI=7.384)
63. Hongyun Zhao, Yuanyuan Zhao, Ying Guo, Yan Huang, Suxia Lin, Cong Xue, Fei Xu, Yang Zhang, Liping Zhao, Zhihuang Hu, Li Zhang.: Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets and Therapy2013; Vol 6:811-818 (SCI=2.073)
64. Jian-Wei Zhang, Yuan-Yuan Zhao, Ying Guo, Cong Xue, Zhi-Huang Hu, Yan Huang, Hong-Yun Zhao, Jing Zhang, Xuan Wu, Wen-Feng Fang, Yu-Xiang Ma, Li Zhang.: The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of advanced non--small cell lung cancer. Chinese journal of cancer 2013;Vol 32(1): (Accepted)
65. Yuankai Shi*, Li Zhang (1)*, Xiaoqing Liu,et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013 Sep;14(10):953-61 (IF 22.589)
66. Xuan Wu,Wenhua Liang,Xue Hou,Zhong Lin,Hongyun Zhao,Yan Huang,Wenfeng Fang,Yuanyuan Zhao,Jinxun Wu,Yunpeng Yang,Cong Xue,Zhihuang Hu,Jing Zhang,Jianwei Zhang,Yuxiang Ma,Ting Zhou,Tao Qin, LiZhang*. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets and Therapy 2013:6 1481–1491 (IF 2.073)
67. Wenfeng Fang，Jianwei Zhang，Wenhua Liang，Yan Huang，Yue Yan，Xuan Wu，Zhihuang Hu，Yuxiang Ma，Hongyun Zhao，Yuanyuan Zhao，Yunpeng Yang，Cong Xue，Jing Zhang，LiZhang* Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis 2013;5(5):585-592
第二、三作者及其他：
1. E1B缺失腺病毒瘤内注射治疗恶性肿瘤的安全性研究.《癌症》2003, 22(3):310-313
2. 423例非小细胞肺癌患者生存的多因素分析.《癌症》2003, 22(6):624-628
3. 表皮生长因子酪氨酸激酶抑制剂ZD1839对鼻咽癌细胞系的作用.《癌症》2004, 23(5)：540-544
4. 表皮生长因子酪氨酸激酶抑制剂Gefitinib对鼻咽癌荷瘤裸鼠移植瘤生长作用的实验研究.《癌症》2004, 23(11s)：1365-1369
5. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng Xiao: Phase III randomized Clinical Trial of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Cisplatin-based Chemotherapy in Treating Squamous Cell Cancer of Head and Neck or Esophagus. Chinese Journal of Cancer 2004; Vol 23(12):1666-1670
6. 雌、孕激素受体在乳腺癌原发灶及复发转移灶之间的表达差异.《癌症》2004, 23(12)：1710-1713
7. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.Comparison of Plasma Epstein–Barr Virus (EBV) DNA Levels and Serum EBV Immunoglobulin A/Virus Capsid Antigen Antibody Titers in Patients with Nasopharyngeal Carcinoma. Cancer 2004;100:1162–70(SCI=4.8)
8. Chen M, Chen YY, Bao Y, Xian CG, Liu GZ, Zhang L, Xu GC, Deng XW, Lu TX, Qian JY, Cui NJ. Neoadjuvant Chemotherapy Followed by Late-Course Accelerated Hyperfractionated Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Long-Term Results of a Phase I/II Clinical Trial. Clinical Lung Cancer 2005, Vol 6(5):304-309(SCI=2.3)
9. 羟基喜树碱在肿瘤病人中的生物利用度研究.《中国临床药理学杂志》2005, 22(1):46-49
10. Tony S.K. Mok, Kwok Chi Lam, Conrad Lee,Li Zhang, Herman Wong,Anthony T.C. Chan, Winnie Yeo, Anthony P.C. Yim, Karen Chak, Benny Zee: Phase II Randomized Study Comparing theToxicity Profile of Gemcitabine plus Cisplatin withGemcitabine plus Oral Etoposide in the Treatmentof Advanced Non-Small Cell Lung Cancer. Oncology 2005; Vol 68:485-492(SCI=1.9)
11. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究.《癌症》2005，24(8)：980-984
12. 结直肠癌患者 DPD 水平与 5-FU血药浓度疗效及毒性的相关性研究.《癌症》2005，24(4)：483-487
13. 柯萨奇病毒腺病毒受体的表达对基因工程腺病毒抗瘤活性的影响.《癌症》2005，24(4)：502-505
14. 116例携带乙肝病毒的淋巴瘤患者化疗后发生肝功能损害的临床分析.《癌症》2005，24(12)：1507-1509
15. 膀胱癌细胞CAR 的表达对E1B缺失腺病毒抗瘤活性的影响.《中山大学学报》2005，26(9)：533-536
16. Li YH, He YF, Jiang WQ, Wang FH, Lin XB,Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.Cancer2006;106(6):1320-1325 (SCI=4.58)
17. Fu Xiao-Hong, Wang Shu-Sen, Huang Yan, Wang Bo, Huang Hui-Qiang, Zhang Li, Sun Xiao-Fei, Xu Rui-Hua, Lin Tong-Yu: Feasibility Study of Application of International Prognostic Score on Prediction of Prognosis of Advanced Hodgkin’s Lymphoma. Chinese Journal of Cancer 2006; Vol 25(8):1013-1018
18.鼻咽癌组织中EGFR和p-ERK蛋白表达及检测意义.《中华肿瘤杂志》2006，28(1)：28-31
19.诱导化疗和紫杉醇每周同期化疗结合三维适形放射治疗不能手术的Ⅲ期非小细胞肺癌的初步结果.《癌症》2006, 25( 10) : 1279- 1283
20. 支气管肺泡细胞癌之中国共识.《循证医学》2006, 6( 4) : 227- 230
21. 老年晚期非小细胞肺癌预后的影响因素分析.《广州医学院报》2007, 35( 5) : 48- 52
22. CPT-11联合 5-FU/CF(FOLFIRI)化疗方案治疗晚期结直肠癌.《 癌症》 2007, 26( 8) : 905- 908
23. 非小细胞肺癌孤立性转移处理共识.《循证医学》2007, 7(2):110-111
24. Wu YL, Zhong WZ, Li LY, Zhang XT,Zhang L,Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T:Epidermal Growth Factor Receptor Mutations and TheirCorrelation with Gefitinib Therapy in Patients withNon-small Cell Lung Cancer: A Meta-Analysis Based onUpdated Individual Patient Data from Six Medical Centersin Mainland China. Journal of Thoracic Oncology 2007; Vol 2: 430–439 (SCI=1.43)
25. FOLFOX 方案一线治疗转移性或复发性晚期大肠癌的疗效分析.《中国肿瘤临床》 2007, 34(24):1418-1421
26. 吉西他滨联合奥沙利铂治疗晚期胰腺癌患者的疗效.《癌症》2007，26(12)：1381-1384
27. 105例老年晚期非小细胞肺癌患者的回顾性分析.《临床肿瘤学杂志》2008,13(5):409-412
28. 非小细胞肺癌ⅢA期 N2 之处理.《循证医学》2008，8(2)：113-117
29. Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ:A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer.Chemotherapy 2008; Vol 54:228-235 (SCI=1.50)
30. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM,Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS:Randomized, Placebo-controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2009; Vol 27:5080-5087 (SCI=17.3)
31. Mok T, Wu YL, Zhang L: A small step towards personalized medicine for non-small cell lung cancer.Discov Med. 2009;Vol 8(43):227-31
32. 孤立性肺结节的处理.《循证医学》2009，9(4)：244-246
33. FOLFIRI 方案对草酸铂治疗失败的晚期结直肠癌的疗效分析.《癌症》2009;Vol 28(9):913-918
34. 局部晚期鼻咽癌诱导加同期化放疗与诱导化放疗的对照研究.《癌症》2009;Vol 28(10):1033-1042
35. Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K:Efficacy and Safety of Erlotinib in 1240 East/South-East Asian Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2010; Vol 5: 1609-161 (SCI=4.547)
36. 贝伐珠单抗治疗非小细胞肺癌的相关不良反应及处理原则.《中国肺癌杂志》2010，13(6)：563-567
37. 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告.《中国肺癌杂志》 2010，13(7)：691-6
38. 紫杉醇联合顺铂每周方案与三周方案治疗老年晚期非小细胞肺癌的临床随机对照研究.《中国肿瘤防治杂志》 2010，17(18)：1463-1466
39. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S,Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE:Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: a randomised, double-blind phase III trial (ZODIAC). Lancet Oncology 2010;Vol 11: 619–26 (SCI= 14.47)
40.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology 2011;Vol 12:735-742 (SCI= 17.76)
41.An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH:Plasma Epstein-Barr virus DNA level strongly predicts survival inmetastatic/recurrentnasopharyngeal carcinoma treated with palliativechemotherapy.Cancer2011;Vol 117(16):3750-7. (SCI=5.131)
42. Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, Wang WH, Liu Y, He H, Chen M:Omitting elective nodal irradiation and irradiating postinduction versuspreinduction chemotherapy tumor extent for limited-stage small cell lung cancer: Interim analysis of a prospective randomized non-inferiority trial.Cancer2012; Vol 118(1):278-287 (SCI= 5.131)
43.Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP, Tian Y:Activation of Notch-1 enhances epithelial-mesenchymal transition ingefitinib-acquired resistant lung cancer cells. J Cell Biochem.2012, Vol 113(5):1501-1513 (SCI= 3.12)
44. Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M:Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Carein Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer:An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial.Journal of Thoracic Oncology 2012; Vol 7(3):567-573
45. Mian Xie, Li Zhang, Chao-Sheng He, Jin-Hui Hou, Su-Xia Lin, Zhi-Huang Hu, Fei Xu and Hong-Yun Zhao: Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2012; Vol 7(5):799-807
46. Luis Paz-Ares, Bonne Biesma, David Heigener, Joachim von Pawel, Timothy Eisen, Jaafar Bennouna, Li Zhang, Meilin Liao, Yan Sun, Assad Chemaissani, SJM Gans, Constantinos Syrigos, Etienne Le Marie, Maya Gottfried, Johan Vansteenkiste, Vincente Alberola, Uwe Phillip Strauss, Elaine Montegriffo, Teng Jin Ong, Armando Santoro, on behalf of the NExUS Investigators Study Group: Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/ Cisplatin Alone or with Sorafenib for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology 2012; Vol 30:3048-3092 (SCI=18.37)
47. Yin-Duo Zeng, Li Zhang, Hai Liao, Ying Liang, Fei Xu, Jun-Ling Liu, Xiao-Xiao Dinglin, Li-Kun Chen: Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.Asian Pacific journal of cancer prevention2012; Vol 13(3):909-914.(SCI=0.66)
48. Y. Sun, Y.-L. Wu, C.-C. Zhou, L. Zhang, L. Zhang, X.-Y. Liu, S.-Y. Yu, G.-L. Jiang, K. Li, S.-K. Qin, S.-L. Ma, L. Han, M. Quinlivan, M. Orlando, X.-Q. Zhang: Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. Lung Cancer2013; Vol 79(2):143-50, (SCI=3.43)
49. Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.: Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012; Vol 8(3):232-243 (SCI=0.58)
50. 吉西他滨联合长春瑞滨方案一线治疗中国晚期非小细胞肺癌患者的多中心回顾性研究。《中国肺癌杂志》2012; Vol 15(5):281-6.
51. 吉西他滨联合长春瑞滨方案治疗复治中国晚期非小细胞肺癌患者的多中心回顾性研究。《中国肺癌杂志》2012; 15(9):507-12.
52. Fang Wang, Sha Fu, Qiong Shao, Yan-Bin Zhou, Xiao Zhang, Xu Zhang, Cong Xue, Jian-Guang Lin,Li-Xia Huang, Li Zhang, Wei-Min Zhang and Jian-Yong Shao：High EGFR copy number predicts benefits fromtyrosine kinase inhibitor treatment for non-smallcell lung cancer patients with wild-type EGFR. Journal of Translational Medicine 2013, Vol 11:90 (SCI=3.47)
53. G. Chen, J. Feng, C. Zhou, Y.-L. Wu, X.-Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou,S. Ren3, S. Lu, L. Zhang, C.-P. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang,X. Zhi, Y. Zhang, Q. Xiu, J. Ma, L. Zhang & C. You: Quality of life (QoL) analyses from OPTIMAL(CTONG-0802), a phase III, randomised, open-labelstudy of first-line erlotinib versus chemotherapy inpatients with advanced EGFR mutation-positivenon-small-cell lung cancer (NSCLC). Annals of Oncology, 2013 (SCI=7.384, Accepted)
54. Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Fatima Fuerte, Gee-Chen Chang, Kasan Seetalarom, Jie Wang, Ashley Cheng, Elisna Syahruddin, Xiaoping Qian, James Ho, Johan Kurnianda, Hsingjin Eugene Liu, Kate Jin, Matt Truman, Ilze Bara, Tony Mok：Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology 2013;Vol 14(8):777-786 (SCI=25.117)
55.会议摘要(2003-2012)：
1. L. Zhang, P.J. Peng, C. Zhao: Randomized Phase II clinical study comparing standard RT with or without weekly Oxaliplatin in treatment of locally advanced NPC: preliminary result. Proc Am Soc Clin Oncol 2003; Vol 21:2003a (Poster)
2. L. Zhang, Y. Zhang, ZZ. Guang: Phase II clinical study of Gemcitabine single agent for patients with advanced Nasopharyngeal Carcinoma (NPC) who failed to first line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2004; Vol 22:5612a (Poster)
3. L. Zhang, X. Zhang, ZK.Pan, X.Wang, N.Li, F. Xu, JH.Chang, ZZ. Guang: The status of epidermal growth factor receptor (EGFR) mutations at exon 19 and 21 in Chinese patients with NSCLC. Proc Am Soc Clin Oncol 2005; Vol 23:7097a (Poster)
4. Y. Zhang, L. Zhang, N. Li, F. Xu, ZK. Pan, ZZ. Guang: Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005; Vol 23:7329a (Poster)
5. Z Guan, L Zhang, L LI, G Jiang, X LIU, D Chu, W Li: A Chinese, Multicentre, Phase II Trial of Gefitinib (Iressa) in Patients with non-Small-Cell Lung Cancer who had Failed Previous Chemotherapy. 11th WCLC, Barcelona, Spain, July 3-6, 2005; Ab 2264
6. L. Zhang, Li Ning, Zhang Xing, Pan Zhen-kui, Wang Xin, Xu Fei, Zhong-zhen Guan: Preliminary Analysis of biomarkers in plasma by SELDI to predict the response to EGFR Tyrosine Kinase Inhibitors (TKIs) in NSCLC patients. Proc Am Soc Clin Oncol 2006; Vol 24:7189a (Poster)
7. Xu Fei, Zhang Li, Li Su, Liao Hai: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor. AACR 2007, Ab 1888
8. B.R.Ghimire, L. Zhang, X. Zhang, S. Li, X. Hou, P.J. Peng: Effects of zoledronic acid on proliferation and synergy with cytotoxic agents in nasopharyngeal carcinoma cell lines. AACR 2007, Ab 3137
9. X. Hou,L. Zhang, C. Zhao, L. Lu, F. Han, S. Li, P. Huang, H. Huang, Z. Guan: Clinical significance of Epstein-Barr virus DNA load detected pre- and post-radiotherapy in nasopharyngeal carcinoma patients. Proc Am Soc Clin Oncol 2007; Vol 25:10558a(Poster)
10. L. Zhang, X. Hou, H. Rao, J. Hou, R. Luo, H. Huang, P. Huang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in respectable non-small cell lung cancer: A retrospective study. Proc Am Soc Clin Oncol 2007; Vol 25:7666a (Poster)
11. R. Xu, B. Han, Y. Shi, J. Xiong, Y. Li, F. Wang, M. Qiu, W. Jiang, T. Lin, L. Zhang, Y. He: Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer. Proc Am Soc Clin Oncol 2007; Vol 25:15062a(Publication)
12. Y. Wu, L. Zhang, J. Siu-Kie Au, A. Cheng, K. Park, H. Kim, V. Srimuninnimit, V. Sriuranpong, M. Lin, H. Kuo, on behalf of the Asia Pacific TRUST investigators: Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): Initial results from the East/South East (E/SE) Asian subgroup. Proc Am Soc Clin Oncol 2007; Vol 25:18018a(Publication)
13. Lin Li-Shan, Zhang Li, Zhang Yang, Wang Zhi-Qiang, Huang He, Zhao Hong-Yun, Guan Zhong-Zhen. Predictive factors of efficacy and survival in Chinese non-small cell lung cancer patients treated with gefitinib. Journal of Thoracic Oncology 2007; Vol 2:S748(Poster)
14.L. Zhang, C. Zhao, B. R. Ghimire, Y. Guo, Z. Z. Guan: The Role of Concurrent Chemo-radiation in the Treatment of Locally Advanced Nasopharyngeal Carcinoma among Endemic Area: A Meta- analysis of the Phase III Randomized Trials. Proc Am Soc Clin Oncol 2008; Vol 26:6032a (Poster Discussion)
15. J. S. Lee, J. Ignacio, C. Yu, C. Zhou, Y. Wu, Y. Chen, L. Zhang, K. Jin, M. Johnston, T. S. Mok.:FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008; Vol 26:8031a (Poster Discussion)
16. K. Lam, T. S. Mok, J. Lee, L. Zhang, Y. Wu, S. Lu, M. Liao, C. Yang, C. Zhou, M. Boyer.: A randomized phase II study of gemcitabine (G) vs gemcitabine/carboplatin (GC) as consolidation therapy to concurrent chemo-radiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC): A Lung Cancer Research Group (LCRG) study. Proc Am Soc Clin Oncol 2008; Vol 26:7559a (Poster)
17. Y. Y. Zhao, C. Q. Zhang, L. P. Lin, X. Wu, J. X. Wu, F. H. Wang, H. Y. Zhao, Z. Z. Guan, L. Zhang: The relationship between circulating VEGF level and outcome of advanced Chinese NSCLC treated with gefitinib. Proc Am Soc Clin Oncol 2008; Vol 27:19074a (Publication)
18. J. X. Wu, H. Y. Zhao, Y. Zhang, Z. Z. Guan, L. Zhang: The relationship between change in tumor size and survival in advanced NSCLC treated with gefitinib. Proc Am Soc Clin Oncol 2008; Vol 26:19066a (Publication)
19. L. Zhang, F.H. Wang, Y.H. Li, Y.J. He, Y. Guo, Z.Z. Guan: The role of oxaliplatin- containing regimens in the treatment of Chinese patients with advanced gastric cancer: a meta-analysis of randomized trials. ESMO 2008, (Poster 534)
20. Y. Wu, T. Mok, D. Chu, B. Han, X. Liu, L. Zhang, C. Zhou, Y. Rukazenkov, E. Duffield, M. Fukuoka: Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Proc Am Soc Clin Oncol 2009; Vol 27:8041a (Poster)
21. Y. Zhao, H. Liao, X. Hou, J. Sun, Y. Guo, S. Li, L. Zhang: A prospective, open-label, randomized phase II trial to evaluate the changes of bone resorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone metastases (BM). Proc Am Soc Clin Oncol 2009; Vol 27:6063a (Poster)
22.J. Wu, H. Bai, G. Zhu, J. Xu, W. Jiang, L. Lin, C. Xue, L. Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib.Proc Am Soc Clin Oncol 2010; Vol 28:10557a (Poster)
23.W. Huang, J. Wu, X. Lin, S. Li, R. Liu, W. Hu, Y. Xia, L. Zhang, W. Jiang, Z. Guan: A multicentre, open-label, randomized phase II trial of adenovirus-mediated endostatin gene therapy in combination with paclitaxel and cisplatin chemotherapy in advanced head and neck carcinoma: Preliminary results.Proc Am Soc Clin Oncol 2010; Vol 28: e16005(Publication)
24.L. Zhang, S. Y. Yu, G. R. Xie, B. Xu, Z. Jiang, S. Lu, H. Wang, Y. Sun; A large, multicenter, retrospective epidemiological survey the incidence and treatment of bone metastatic disease in Chinese cancer patients. Proc Am Soc Clin Oncol 2010; Vol 28:e19612(Publication)
25.H. Zhao, G. Chen, J. F. Feng, Y. Chen, Y. Zhang, X. Song, Y. Huang, L. Zhang; A phase II study of erlotinib plus capecitabine (XEL) as first line treatment for elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study).Proc Am Soc Clin Oncol 2010; Vol 28:e18016(Publication)
26.L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu, L. Yun-Peng, M. Wang, X. Zhang: Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in China (INFORM) (C-TONG 0804). Proc Am Soc Clin Oncol 2011; Vol 29:LBA7511 (Oral)
27.Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. H. Chang, X. Song, J. Liang, H. Liang, J. Hu, S. Y. Yu, J. Chen, J. Wang, H. M. Pan, A. Carides, D. Chitkara: A 3-day oral aprepitant regimen provides superior prevention of CINV over standard therapy in Chinese patients receiving high-dose cisplatin. Proc Am Soc Clin Oncol 2011; Vol 29:9105 (Poster)
28.Y. Sun, Y. Shi, L. Zhang, X. Q. Liu, C. Zhou, L. Zhang, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Song, J. F. Feng, Y. Cheng, H. Zhang, Y. L. Wu, N. Xu, J. Zhou: A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).Proc Am Soc Clin Oncol 2011; Vol 29:7522(Poster)
29.S. Lu, L. Zhang, Y. L. Wu, Y. Zhang, C. Zhou, G. Chen, M. Hou, X. Song, J. Wang：An observational study on the efficacy and safety of zoledronic acid (ZA) in non-small cell lung cancer (NSCLC) patients with bone metastases with high urine n-telopeptide (uNTX) at diagnosis (C-TONG 0801).Proc Am Soc Clin Oncol 2011; Vol 29: e19541(Publication)
30.C. Zhou, Y. L. Wu, G. Chen, J. F. Feng, X. Q. Liu, C. L. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang：Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).Proc Am Soc Clin Oncol 2011; Vol 29:7520(Poster)
31. Yi-long Wu, Caicun Zhou, Li Zhang, Reury-Perng Perng, Tony Mok: Efficacy of erlotinib across clinical subgroups in Chinese patients and a broader Asian subpopulation with advanced non-small-cell lung cancer (NSCLC): sub-analysis of the TRUST study. Journal of Thoracic Oncology 2011; (ab P3.102) (Poster)
32.C. Xue, J. J. Pan, X. Song, Y. Zhang, Q. Yu, S. Lin, J. Wu, Y. Zhao, W. Jiang, L. Zhang: Phase II study of combination of sorafenib with cisplatin and 5-fluorouracil as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2012;Vol 30:5538 (Poster)
33. Li Zhang, Meiqi Shi, Cheng Huang, Xiao-Qing Liu, Jian ping Xiong, Gongyan Chen, Wei Liu, Wenchao Liu, Yiping Zhang, Kai Li: A phase II, multi-center, Placebo controlled trial of apatinib in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after 2 previous treatment regimens.Proc Am Soc Clin Oncol 2012;Vol 30:7548 (Poster)
34. Tony Mok, Yi-long Wu, Sumitra Thongprasert, Chong-Jen Yu,Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Kate Jin, Matt Truman, Jin Soo Lee: A randomized placebo-controlled phase 3 study of intercalated erlotinib with gemcitabine/platinum in 1st-line advanced non-small-cell lung cancer (NSCLC): FASTACT-2. Proc Am Soc Clin Oncol 2012; Vol 30:7519 (Poster Discussion)
35. Caicun Zhou, Yi-long Wu, Xiaoqing Liu, Changli Wang, Gongyan Chen, Jifeng Feng, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chenghong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiyuyi Zhi, Yiping Zhang, Qingyu Xiu: Overall survival (OS) results from OPTIMAL, a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012; Vol 30:7520 (Poster Discussion)
36. Liping Zhao, Wanli Liu, Chong Zhao, Xiang Guo, Yan Huang, Fei Xu, Zhihuang Hu, Zhiqiang Wang, Hongyun Zhao,Li Zhang: Pharmacokinetic and pharmacodynamic analysis of fluorouracil in nasopharyngeal cancer patients. Proc Am Soc Clin Oncol 2012;Vol 30:e13021 (Publication)
37. Pierre Ferre, Zhimin Shao, Zefei Jiang, Dafang Zhong, Chen Xiaoyan, Jean-Philippe Burillon, Aurélie Petain, Grégoire Zorza, Li Zhang:Is vinorelbine pharmacokinetics modified in Asian patients when compared to Caucasian patients? Proc Am Soc Clin Oncol 2012; Vol 30:e13036 (Publication)
38. Shun Lu, Lu Li, Yi Luo, Li Zhang, Zhiwei Chen, Wu Gang, Ping Chen, Cheng Huang, Shuliang Guo Sr., Yiping Zhang, Xiangqun Song, Meijun Lv, Wei Li, Chunhong Hu, Chengping Hu: Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392). Proc Am Soc Clin Oncol 2012; Vol 30:7091(Poster)
39. Yan Sun, Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, LI Zhang, Dong Wang, Qiang Li, Shucai Zhang, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Yong Song, Ji Feng Feng, Ying Cheng, Helong Zhang, Yi Long Wu, Nong Xu, Jianying Zhou: Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. Proc Am Soc Clin Oncol 2012;Vol 30:7559 (Poster)
40. T.S.K. Mok, J.S. Lee, L. Zhang, C.-J. Yu, S. Thongprasert, G.E.I. Ladrera, V. Srimuninnimit, M.I. Truman, B. Klughammer, Y.-L. Wu: Biomarker analysis and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced Non-small cell lung cancer (NSCLC).ESMO 2012, (1226O)
41. S. Yan, S. Yuankai, Z. Li, L. Xiaoqing, C. Zhou, Z. Li, W. Dong, L. Qiang, Z. Shucai, S. Qin：Final overall survival and update biomarker analysis results from the randomized phase III ICOGEN trial. ESMO 2012, (1269P)
42. M. Xie and Z. Li:Preclinical anti-tumor activity of xl880 in nasopharyngeal carcinoma.ESMO 2012, (1027P)
43. L.Zhao,W.Liu, X.Guo, C.Zhao, Y.Huang, F.Xuand L. Zhang:Pharmacokinetic and pharmacodynamic analysis of 5-fluorouracil in chinese head and neck cancer (hnc) patients.ESMO 2012, (1057P)
44. L. Paz-Ares, V. Hirsh,L. Zhang, F. De Marinis, J.C-H. Yang, H. Wakelee,T. Seto, T. Schmelter, T.J. Ong, T.S.K. Mok, E.F. Smit: Monotherapy administration of sorafenib inpatients with non-small cell lung cancer:phase iii, randomized, double-blind,placebo-controlled MISSION trial.ESMO 2012, (LBA33 PR)
45. Y. Wu,Z. Li, C. Zhou, L. Shun, Y. Zhang, M. Hou, W. Liu, J. Wang,G. Chen, Y. Zhou: Multi-center observational study on the diagnosisof non-small cell lung cancer bone metastasisand the efficacyand safety of bisphosphatestreatment (C-TONG 0801).ESMO 2012,(1359P)
46. Q. Zhou, C. Zhou, G. Chen, Y. Cheng, C. Huang, L. Zhang, Y-L Wu:A phase II study of sorafenib monotherapy in thepatients with advanced or recurrentnon-small-cell lung cancer after failure ofEGFR-TKI (C-TONG0805).ESMO 2012,(1362TiP)
47. Li Zhang, Shun Lu, Ying Cheng, Zhihuang Hu, Zhiwei Chen, Gongyan Chen, Xiaoqing Liu, Jinji Yang, Li Zhang, Jia Chen, Meijuan Huang, Min Tao, Gang Cheng, Cheng Huang, Caicun Zhou, Weimin Zhang, Hong Zhao：Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904). J Clin Oncol 31, 2013 (suppl; abstr 8015) (Poster Discussion)
48. Wenhua Liang, Li Zhang： Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 31, 2013 (suppl; abstr 8089) Poster
49. Yan Huang, Li Zhang, Jian-ji Pan, Guoqing Hu, Wu Gang, Jian ping Xiong, Chaosu Hu, Lizhu Lin, Hao Yu, Haoyuan Jiang：A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens. J Clin Oncol 31, 2013 (suppl; abstr 6026)
参加临床研究的情况：
作为主要研究者(Principle Investigator and/or Steering Committee member)的研究:
1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemona?ve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member)
2. A multicentre, double-blind randomised, phase III trial to assess the efficacy of Iressa 250mg for Maintenance therapy Following Induction Treatment for Advanced Non Small Cell Lung Cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy(INFORM Study) (NCT00769639)(C-TONG 0804). (Principle Investigator and Steering Committee member)
3. A phase II/III randomized, double-blind study of paclitaxel plus carboplatin in combination with vorinostat (MK-0683) or placeboin patients with stage IIIB (with pleural effusion) or stageIV non-small-cell lung cancer (NSCLC)(NCT00473889).(Steering Committee member)
4. Efficacy and Safety Study of ZOMETA® in Treatment of High-Level NTX Non Small Cell Lung Cancer With Bone Metastasis (ZEST study) (NCT00762346).(Principle Investigatorand Steering Committee member)
5. A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (FAST-ACT-II) (NCT00883779).(Steering Committee member)
6. International randomized study to evaluate the addition of docetaxel to thecombination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF)in the induction treatment of nasopharyngeal carcinoma (NPC) in childrenand adolescents(NCT00565448) (Steering Committee member)
7. A Randomised phase II study of oral Vinorelbine in combination with cisplatin versus IV Vinorelbine in combination with cisplatin in unresectable localized or metastatic NSCLC (PM 0259 CA 225 J1).(Principle Investigator)
8. Phase II study of combination of Sorafenib with cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)(NCT00747799).(Principle Investigator)
9. Study of Alimta in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have had prior platinum based chemotherapy(NCT00630149).(Principle Investigator)
10. To evaluate the efficacy of ZOMETA® in treatment of bone metastases in patients with stage IV nasopharyngeal cancer (NCT00697619).(Principle Investigator)
11. A Study of TX Regimen as First-Line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-Small Cell Lung Cancer (NCSLC)(NCT00816868).(Principle Investigator)
12. A randomized, multi-centre, double-blind, placebo-controlled, parallel-group comparison study to investigate the safety, tolerability and efficacy of MK-0869 for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with high-dose cisplatin (NCT00952341).(Principle Investigator)
13. A randomized, multi-centre open-label phase III study of first line treatment using pemetrexed/cisplatin versus gemcitabine/cisplatin in non-squamous lung cancer (NCT01194453).(Principle Investigator)
14. A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (ATTRACT-2)(NCT00738387)(Steering Committee member)
15. A Phase III, Multi-centre, Placebo-controlled Trial of Sorafenib (BAY 43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens.(MISSION trial) (NCT00863746).(Steering Committee member)
16. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as AdjuvantTherapy in Patients With Resectable MAGE-A3 Positive NSCLC (NCT00480025).(Steering Committee member)
17. Gefitinib 500mg versus 250mg in patients with Non-Small Cell Lung Cancer (NSCLC) with stable disease after a month treatment of Gefitinib 250mg (NCT01017679).(Principle Investigator)
18. A Phase III, Randomized, Double-blinded,Multi-center Study to Assess the Efficacy of Icotinib (ICOGEN?)versus Gefitinib in Patients with Locally Advanced or Metastatic (Stage IIIb–IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st/2 Line Chemotherapy (ChiCRT-TRC-00000505)(NCT01040780).(Co-Principle Investigator)
19. Taxotere Combined with Cisplatin for First-line chemotherapy with different dose and then maintenance therapy (C-TONG0904) (NCT01038661，TrialTroveID-120637). (Principle Investigator)
20. A study of Apatinib in Patients with Advanced Non-squamous Non-small Cell Lung Cancer(Phase II) ( NCT001270386).(Principle Investigator)
21. Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer(Phase III)( NCT01287962).(Principle Investigator)
22. Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography (NCT01347424). (Principle Investigator)
23. A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors (NCT01148615).(Principle Investigator)
24. Famitinib in Treating Patients With Recurrent and/or Metastatic nasopharyngeal carcinoma (NCT01392235). (Principle Investigator)
25. A randomized, control, multicenter phase III clinical trial comparing gemcitabine and cisplatin with 5-Fu and cisplatin in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) (NCT01528618). (Principle Investigator)
26. Randomized Double-Blind Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC (NCT01528488). (Co-Principle Investigator)
27. A Phase I Study of continuous intravenous infusion Endostatin plus AC Regimen intreatingPatients With Advanced Adenocarcinoma of Lung(NCT01531790). (Principle Investigator)
28. Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors.( NCT01226030) (Principle Investigator)
作为参加者的研究(Participant Trail):
1. International, randomized, open-label, phase IIItrial of paclitaxel/carboplatin plus PF 3512676 Versuspaclitaxel/carboplatin aloneasfirst-linetreatment ofpatients with advanced non-small cell lung cancer.(NCT00254891)
2. A Randomized, double-blind study to evaluate the effect of Tarceva or placebo following platinum-based chemotherapy on overall survival and disease progression in patients with advanced, recurrent or metastatic Non-small Cell Lung Cancer (NSCLC) who have not experienced disease progression (STARTUN) (NCT00556712).
3. An open-label, randomized study to evaluate the effect of Tarceva, compared with Alimta (Pemetrexed) or Taxotere (Docetaxel),on survival in patients with advanced, recurrent or metastatic Non-small Cell Lung Cancer who have experienced disease progression during platinum-based chemotherapy (TITAN) (NCT00556322).
4. A phase III, randomized, double-blinded, multi-center study to assess the efficacy of docetaxel (TAXOTERE?) in combination with ZD6474 (ZACTIMA?) versus docetaxel (TAXOTERE?) in combination with placebo in patients with locally advanced or metastatic (Stage IIIb–IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy(NCT00312377)
5. OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer(TRUST trial) (NCT00036647).
6. Open-label study of bevacizumab (Avastin®) in combination withplatinum-containing chemotherapy as first-line treatment ofpatients with advanced or recurrent non-squamous non-smallcell lung cancer (NSCLC) (SAiL Study) (NCT00700180).
7. Phase III, randomised, open-label, first-line study of gefitinib(G) Vs carboplatin/ paclitaxel (C/P) in clinicallyselectedpatients with advanced non-small-cell lung cancer (NSCLC)(IPASS Study) (NCT00322452).
8. A Randomized Phase II Study of Gemcitabine (G) versus Gemcitabine/Carboplatin (GC) as Consolidation Therapy to Concurrent Chemo-radiotherapy (CRT) for Stage III Non-Small Cell Lung Cancer (NSCLC): A Lung Cancer Study Group (LCRG) Study.
9. FAST-ACT: a phase II randomized double-blind trial of sequential erlotinib and chemotherapy as 1st-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)(NCT00940875).
10. A trial comparing gemcitabine, cisplatin and sorafenib to gemcitabine, cisplatin and placebo in first-line treatment of stage IIIb with effusion and stage IV non-small cell lung cancer (NSCLC) (NExUS study，NCT00449033).
11. Bisphosphonates Lung cancer Efficacy and Safety Trial (BLEST study)(NCT00765687).
12. Randomized, Open-Label, phase 3 Trial Comparing Amrubicin Combined With Cisplatin Versus EP as First-Line Treatment in Patients With Extensive Disease SCLC (NCT00660504)
13. A Multi-Center Phase III Randomized, Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax® (BLP25 Liposome Vaccine) in NSCLC Subjects with Unresectable Stage III Disease. (NCT00409188).
14. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)(ATTRACT-1)(NCT00662597).
15. An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The AnaplasticLymphoma Kinase (ALK) Gene(NCT00932451 ).
16. An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene(NCT00932893).
17. An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase(ALK)( NCT01121588)
18. LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer (NCT00805194)
19. A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors (NCT01626209)
20. LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy (NCT01523587)
21. LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung ( NCT01466660)
22. A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer ( H3E-CR-JMIT) (NCT01469000)
23. A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients ( NCT01639001)
24. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4) (NCT01524783)
25. Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (NCT01297491)
26. A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment (NCT01610336)
27.Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone(NCT01450761)
28. Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (NCT01285609)
参加独立数据管理委员会(IDMC)
1. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination with Paclitaxel versus Paclitaxel plus Placebo in Subjects with ErbB2 Amplified Metastatic Breast Cancer(IDMC member)
2. LUX-Lung 6 study: A randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with Stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation(IDMC member)
3. INSPIRE study: A multi-national, double-blind, placebo-controlled,randomized, phase III clinical trial of the cancervaccine Stimuvax® (L-BLP25 or BLP25 liposomevaccine) in Asian subjects with stage III,unresectable, non-small cell lung cancer (NSCLC)who have demonstrated either stable disease orobjective response following primarychemo-radiotherapy.(IDMC member)
4. The controlled trial of Tegafur, Gimeracil and Oteracil Potassium Capsule plus Cisplatin in untreated patients with advanced lung cancer(IDMC member)
5. A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (IDMC Chairmen)
